![Michael Lyle](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Michael Lyle
Chief Tech/Sci/R&D Officer at Welichem Biotech, Inc.
Profile
Michael Lyle is currently the Vice President of Research & Development at Welichem Biotech, Inc. He obtained a doctorate degree from Simon Fraser University.
Michael Lyle active positions
Companies | Position | Start |
---|---|---|
Welichem Biotech, Inc.
![]() Welichem Biotech, Inc. Pharmaceuticals: MajorHealth Technology Welichem Biotech, Inc. operates as a drug discovery and early stage drug development company focusing on novel therapeutics for autoimmune, inflammatory diseases and cancers. The firm's focus has been on research and development of its novel anti-inflammatory drug candidate, WBI-1001 and its derivatives, and its anticancer drug candidate, WBI-2100 and its derivatives. The company was founded on November 1, 2004 and is headquartered in Burnaby, Canada. | Chief Tech/Sci/R&D Officer | 01/12/2009 |
Training of Michael Lyle
Simon Fraser University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 1 |
---|---|
Welichem Biotech, Inc.
![]() Welichem Biotech, Inc. Pharmaceuticals: MajorHealth Technology Welichem Biotech, Inc. operates as a drug discovery and early stage drug development company focusing on novel therapeutics for autoimmune, inflammatory diseases and cancers. The firm's focus has been on research and development of its novel anti-inflammatory drug candidate, WBI-1001 and its derivatives, and its anticancer drug candidate, WBI-2100 and its derivatives. The company was founded on November 1, 2004 and is headquartered in Burnaby, Canada. | Health Technology |
- Stock Market
- Insiders
- Michael Lyle